RECRUITING Phase 1 ClinicalTrials.gov

Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor: Epitopea Ltd • ClinicalTrials.gov ID: NCT07665515

Registry updated: 2026-10-16

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer. The most common and aggressive form is called high-grade serous ovarian cancer. The main purpose of this study is to understand whether an experimental study vaccine, CryptiVax-1001, is safe when administered to patients with high-grade serous ovarian cancer (HGSOC). The study vaccine is a cancer vaccine, which aims to delay or possibly prevent the cancer from coming back. However, as this is the first study of the vaccine in patients, the primary purpose of this study is to assess the safety of the study vaccine. Following surgery and platinum-based chemotherapy participants may enter the trial and receive CryptiVax-1001 as an explorative maintenance therapy. The main purposes of this study are therefore to: * assess how well the study vaccine is tolerated and identify any side effects. * analyse the study vaccine's capacity to activate your immune system The study will test escalating dose levels of CryptiVax-1001 based on the safety evaluations to estimate appropriate future dose levels for CryptiVax-1001.

Interventions

CryptiVax-1001 (Biological)
i.m injection

Eligibility criteria

Inclusion Criteria: * Able to comprehend and are willing to sign the ICF and willing to follow the study procedures * Female, aged 18 years of age or older at the time of informed consent. * Histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma of high-grade serous histology or other high-grade predominantly serous subtypes * The FIGO 2014 stage III or IV disease at initial diagnosis. * Underwent optimal PDS or IDS with residual disease ≤1 cm (R0 or R1 resection) * Completed first-line platinum-based chemotherapy (minimum 4 cycles of carboplatin and paclitaxel, or equivalent, received in either neoadjuvant or adjuvant, or both settings). * In the presence of measurable target lesion, achieved CR or PR per investigator assessment based on RECIST 1.1 after completion of chemotherapy. In the absence of measurable target lesion, no new lesion or overt progression per investigator assessment based on RECIST 1.1 after completion of chemotherapy. * A minimum of 4 weeks from screening since the last dose of first-line platinum-based chemotherapy but not more than 12 weeks from screening since the last dose of first-line platinum-based chemotherapy. * No evidence of radiologic or clinical progression between the end of chemotherapy and baseline screening. * Known BRCAwt status. * HRP confirmed * No prior, current, or planned treatment with bevacizumab or PARPi in the first-line maintenance setting. * ECOG performance status of 0 or 1. * Adequate haematologic and organ function * Negative pregnancy test for WOCBP. * HLA type matching Cryptivax-1001 Exclusion Criteria: * Non-epithelial or low malignant potential ovarian tumours * Presence of uncontrolled ascites or pleural effusion requiring drainage within 4 weeks of screening. * Concurrent malignancy or history of another malignancy within the past 3 years except for malignancies with a negligible risk of metastasis or death * Active autoimmune disease requiring systemic immunosuppression * Uncontrolled intercurrent illness that, in the opinion of the investigator, would compromise participant safety or interfere with study assessments * History of anaphylactic reaction to mRNA-LNP therapies. * Previous treatment with any cancer vaccine, checkpoint inhibitor, or adoptive cellular immunotherapy. * Administration of any vaccine within 30 days prior to first dosing. * Participation in a clinical study involving administration of an IMP (new chemical entity) in the past 90 days or 5 half-lives of that drug (if known) prior to first dosing, whichever is longer.

Conditions

Ovarian Cancer HGSOC HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Locations

Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital — Cambridge, United Kingdom
The University of Edinburgh - Western General Hospital - Edinburgh Cancer Research Centre — Edinburgh, United Kingdom
Beatson West of Scotland Cancer Centre — Glasgow, United Kingdom
St. James's University Hospital — Leeds, United Kingdom
University Hospitals of Leicester NHS Trust -Leicester Royal Infirmary — Leicester, United Kingdom
University College London Hospitals NHS Foundation Trust - Cancer Clinical Trials Unit — London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital — London, United Kingdom
Royal Marsden NHS Foundation Trust - Royal Marsden Hospital — London, United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust - Royal Preston Hospital — Preston, United Kingdom
Royal Marsden NHS Foundation Trust - Institute of Cancer Research — Sutton, United Kingdom

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment